Qiagen (NYSE:QGEN) Receives $47.71 Average Target Price from Analysts

Shares of Qiagen (NYSE:QGEN) have been given an average rating of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $47.71.

A number of research analysts recently commented on QGEN shares. Morgan Stanley restated an “equal weight” rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Robert W. Baird downgraded shares of Qiagen from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $52.00 to $42.00 in a report on Wednesday, February 19th. Jefferies Financial Group reissued a “buy” rating and issued a $52.50 target price (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, UBS Group lowered their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Brown Brothers Harriman & Co. bought a new position in Qiagen in the 4th quarter valued at $37,000. Geneos Wealth Management Inc. raised its holdings in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after buying an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after buying an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Qiagen during the 3rd quarter worth about $53,000. Finally, Smartleaf Asset Management LLC increased its position in Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock valued at $63,000 after acquiring an additional 835 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Price Performance

Shares of Qiagen stock opened at $39.86 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a market cap of $8.84 billion, a PE ratio of 111.00, a price-to-earnings-growth ratio of 2.39 and a beta of 0.44. The firm has a fifty day moving average price of $40.82 and a two-hundred day moving average price of $42.13. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Analysts expect that Qiagen will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.